ACADIA’s history is rooted in science and strong leadership in central nervous system (CNS) research. Since the beginning, we have been dedicated to improving the lives of patients suffering from CNS disorders. We invite you to learn more about our history.

2019

ACADIA initiates Phase 3 CLARITY program with pimavanserin as adjunctive treatment for major depressive disorder and completes enrollment in ENHANCE and ADVANCE schizophrenia trials.

ACADIA initiates Phase 3 CLARITY program with pimavanserin as adjunctive treatment for major depressive disorder and completes enrollment in ENHANCE and ADVANCE schizophrenia trials.

2018

ACADIA adds trofinetide to CNS pipeline and reports positive Phase 2 CLARITY results for pimavanserin as adjunctive treatment for major depressive disorder.

ACADIA reports positive Phase 2 CLARITY results for pimavanserin as adjunctive treatment for major depressive disorder.

ACADIA signs exclusive North American license agreement for the development and commercialization of trofinetide for Rett syndrome.

FDA approves new dosing formulation and strength for NUPLAZID® (pimavanserin).

Phase 2 data for pimavanserin in patients with dementia-related psychosis published in The Lancet Neurology.

2017

FDA grants Breakthrough Therapy Designation to pimavanserin for dementia-related psychosis.

FDA grants Breakthrough Therapy Designation to pimavanserin for dementia-related psychosis.

ACADIA named one of Forbes' “Most Innovative Growth Companies” (#11 of 100).

2016

FDA approves NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA announces positive results in Alzheimer's disease psychosis and initiates studies with pimavanserin for major depressive disorder and schizophrenia.

ACADIA reports positive Phase 2 data for pimavanserin in patients with Alzheimer's disease psychosis.

ACADIA initiates ENHANCE Phase 3 trial with pimavanserin as adjunctive treatment for schizophrenia with inadequate response to current antipsychotic treatment and ADVANCE Phase 2 trial with pimavanserin as adjunctive treatment for negative symptoms of schizophrenia.

ACADIA is added to Large-Cap Russell 1000 Index.

FDA approves NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

2015

ACADIA submits NUPLAZID® (pimavanserin) New Drug Application for Parkinson’s disease psychosis to the U.S. FDA and is granted Priority Review.

ACADIA submits NUPLAZID® (pimavanserin) New Drug Application for Parkinson’s disease psychosis to the U.S. FDA and is granted Priority Review.

Steve Davis appointed President and Chief Executive Officer.

2014

ACADIA receives FDA Breakthrough Therapy Designation for NUPLAZID® (pimavanserin) for Parkinson's disease psychosis.

ACADIA receives FDA Breakthrough Therapy Designation for NUPLAZID® (pimavanserin) for Parkinson's disease psychosis.

ACADIA announces trade name NUPLAZID® for pimavanserin.

2013

Phase 3 data for pimavanserin in patients with Parkinson’s disease psychosis presented at the American Academy of Neurology and published in The Lancet.

The Lancet publishes data from the Phase 3 study with pimavanserin for Parkinson’s disease psychosis.

ACADIA is added to the NASDAQ Biotechnology and the Russell 2000 indices.

After meeting with the FDA, ACADIA announces an expedited path to a New Drug Application filing with pimavanserin for the treatment of Parkinson’s disease psychosis.

Phase 3 data with pimavanserin for Parkinson’s disease psychosis is presented at the American Academy of Neurology Annual Meeting.

2012

ACADIA reports positive Phase 3 data for pimavanserin in patients with Parkinson’s disease psychosis.

ACADIA reports positive Phase 3 data for pimavanserin in patients with Parkinson’s disease psychosis.

2010

ACADIA initiates Phase 3 study in Parkinson’s disease psychosis.

ACADIA initiates a pivotal Phase 3 efficacy, tolerability, and safety study with pimavanserin in patients with Parkinson’s disease psychosis.

ACADIA regains full worldwide rights to pimavanserin following the conclusion of its collaboration with Biovail.

2009

ACADIA forms collaboration with Biovail to develop and commercialize pimavanserin in North America.

ACADIA forms collaboration with Biovail to develop and commercialize pimavanserin in North America.

2007

ACADIA reports positive Phase 2 data for pimavanserin as a co-therapy for patients with schizophrenia.

ACADIA reports positive Phase 2 data for pimavanserin as a co-therapy for patients with schizophrenia.

2006

ACADIA reports positive Phase 2 data for pimavanserin in patients with Parkinson’s disease psychosis.

ACADIA reports positive Phase 2 data for pimavanserin in patients with Parkinson’s disease psychosis.

2004

ACADIA completes its initial public offering and trades under the symbol “ACAD” on the NASDAQ Stock Market.

ACADIA completes its initial public offering and trades under the symbol “ACAD” on the NASDAQ Stock Market.

2001

Pimavanserin first synthesized by an ACADIA chemist.

Pimavanserin is synthesized by an ACADIA chemist working in the Copenhagen facility.

1999

ACADIA scientists start a project aimed at discovering 5-HT2A inverse agonists.

ACADIA scientists start a project aimed at discovering new non-dopaminergic antipsychotic agents selectively acting as inverse agonists on the 5-HT2A receptor.

1997

Company changes its name to ACADIA Pharmaceuticals Inc. and moves headquarters to San Diego.

The company changes its name to ACADIA Pharmaceuticals Inc. and shifts its strategic focus to discovering and developing its own portfolio of product candidates. ACADIA’s headquarters is moved from Winooski, Vermont, to the biotech hub of San Diego and the company simultaneously establishes medicinal chemistry operations in Copenhagen, Denmark. Funding to support the growing operations comes from a consortium of Danish investors. The company is named after ACADIA National Park based on its historic ties to New England and the limitless power and beauty that the park inspires.

ACADIA establishes its first of several drug discovery and development collaborations with Allergan.

1993

Receptor Technologies is founded by Mark Brann, Ph.D., a professor at the University of Vermont.

Receptor Technologies is founded by Mark Brann, Ph.D., a professor at the University of Vermont. The company initially works with major pharmaceutical companies to perform high-throughput screening based on its proprietary functional genomics platform, R-SAT.